Navigation Links
SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
Date:7/24/2014

Bound Brook, NJ (PRWEB) July 24, 2014

As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion.

"We are delighted to have a preferred provider agreement with DZS to manage our clinical trials globally and in particular in the MENA region,” said Global VP of R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh Rehani. "DZS has developed excellent operational practices with a focus on utilizing eClinical software and flexible team structures that allow companies to reduce development costs yet maintain high quality services and meet timelines. This helps pharma companies to meet the many challenges of drug development."

“We are pleased to be able to partner with SBI at a strategic level. Our Sponsors are increasingly looking for innovative approaches to bring products to market effectively and efficiently,” said Greg Ambra, VP of Clinical Operations. “Our flexible project team models, collaborative approach, and proprietary eClinical Software, ClinPlus®, increases the level of collaboration and allows us to respond quickly to our Sponsor’s needs, while maintaining our focus on high quality deliverables.”

About DZS Clinical Services:
DZS Clinical Services is a full-service Contract Research Organization providing clinical trial services and eClinical software for the biotech and pharmaceutical industry. DZS Clinical Services is a division of DZS Software Solutions, Inc., a privately held company founded in 1984. Over 60 clients globally use DZS services and software for trial monitoring and management, data capture, data cleaning, analysis, and reporting. When ClinPlus® software is coupled with DZS services and training, clients have dramatically improved productivity and maximized the value of R&D investments by obtaining fast, high-quality results leading to better decisions.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12038943.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
2. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
3. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
4. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
5. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
6. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
7. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
8. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
9. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
10. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
11. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , ... January 12, 2017 ... ... VTI’S INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the ... InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has ...
(Date:1/12/2017)... January 12, 2017 The Energy ... biggest facility for producing mycorrhizae. The Centre for Mycorrhizal ... potential of mycorrhizae and developed a technology that eventually ... ... The TERI facility has a production ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... ... 11, 2017 , ... With sepsis claiming approximately 500,000 lives ... billion, healthcare systems are looking to provide better and faster care to ... are bacteria and the yeast pathogen Candida, which can lead to severe complications ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):